Loading
A phase 2 trial of NHWD-870 run by Zhejiang Wenda Pharma Technology LTD., of unknown status on the registry.
A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer is a phase 2 interventional study registered as NCT06527300 by Zhejiang Wenda Pharma Technology LTD., with 48 participants planned, started 2024-04-25. Conditions recorded: Advanced Solid Tumor (Phase 1). Interventions recorded: NHWD-870 HCl.
Shares NHWD-870, Zhejiang Wenda Pharma and the tag pipeline.
Shares Zhejiang Wenda Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Zhejiang Wenda Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/